FindTrial
Sign In

Later-line therapy

DRUG3 trials

Sponsors

Peking Union Medical College Hospital

Conditions

Advanced CancerLocally AdvancedMetastatic CancerPancreatic CancerResectable Carcinoma

Unknown Phase

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
RecruitingNCT05802407
Peking Union Medical College HospitalPancreatic Cancer, Resectable Carcinoma
Start: 2023-02-01End: 2030-02-01Target: 100Updated: 2023-04-12
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer
RecruitingNCT05802394
Peking Union Medical College HospitalLocally Advanced, Pancreatic Cancer
Start: 2023-02-01End: 2030-02-01Target: 100Updated: 2023-04-12
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer
NCT05802420
Peking Union Medical College HospitalAdvanced Cancer, Metastatic Cancer, Pancreatic Cancer
Start: 2023-02-01End: 2025-02-01Target: 100Updated: 2023-04-12